One of the world’s most promising experimental COVID-19 vaccines, developed by Oxford University and AstraZeneca, elicited a strong immune response in older adults, making it a vaccine that covers the maximum age-spectrum possible.
The under-development vaccine induced a lower adverse response in the elderly, AstraZeneca who is manufacturing the doses said in a statement on Monday, Reuters news agency reported.
The same vaccine development was briefly paused in September, in the UK, US, Brazil, and India following an illness in one of the patients. But since then trials were continued gradually.
A vaccine that performs well in the critical stage of clinical trials is being seen as a game-changer during the pandemic. Hope for a vaccine that will control the disease that has already infected over 39 million is high among the public.
The WHO has said earlier, never in the history of humankind a vaccine developement was under so much pressure than during this COVID-19 pandemic.
Vaccines, which involve years of development to become finally available for mass jabbing is now being pushed by government s across the world to fast-track the progress, like never before.
“It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher,” an AstraZeneca spokesman told Reuters news agency.
Over 1.5 million people have already died from the virus and have deeply crippled the global economy, and lives of billions of people globally.
Meanwhile, US infectious disease expert Dr. Anthony Fauci said the world will know by November end to December onset if a COVID-19 vaccine will be ready for mass administration.
“When you talk about vaccinating a substantial proportion of the population so that you can have a significant impact on the outbreak, that very likely will not be until the second or third quarter of the year,” Fauci told the BBC.
A vaccine that enacts a strong immune response in older adults is key for its efficacy since with age people become more susceptible to become severely ill with the virus.
Vaccines from Johnson & Johnson, Moderna showed promising results in protecting the older populations from the virus, which attacks the respiratory system in humans, after infection, We The World reported.